Hologic, Inc. with ticker code (HOLX) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $95.00 and $78.00 with the average target price sitting at $86.62. Given that the stocks previous close was at $71.43 this is indicating there is a potential upside of 21.3%. It’s also worth noting that there is a 50 day moving average of $75.00 and the 200 day MA is $72.85. The company has a market capitalization of 16.68B. The stock price for the company is currently $71.47 USD
The potential market cap would be $20,226,435,379 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 36.84, revenue per share of $16.39 and a 6.22% return on assets.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women’s health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics segment offers a range of diagnostics products, such as ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Its Breast Health segment offers a portfolio of solutions for breast cancer care, primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment offers a range of products, such as NovaSure Endometrial Ablation System, MyoSure Hysteroscopic Tissue Removal System and Fluent Fluid Management system as well as its Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, and the Fluoroscan Insight FD mini C-arm.
